NBQX, an AMPA antagonist, reduces glutamate-mediated brain edema.
Glutamate (2.5 mg) was administered after the blood-brain barrier had been opened by a unilateral intracarotid infusion of 5 mg protamine sulfate in rats. Whereas the brain specific gravity, measured 24 h later, did not differ between the injected and non-injected side after protamine alone, glutamate significantly reduced the specific gravity in the right hemisphere indicating brain edema (P less than 0.01). NBQX, a potent AMPA receptor antagonist, significantly reduced the edema (P less than 0.01) and completely inhibited the glutamate mediated increase in albumin content in cerebrospinal fluid (P less than 0.01).
Westergren
I
I
Department of Neurology, Lund University Hospital, Sweden.
Johansson
B B
BB
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D001929:Brain Edema / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D005971:Glutamates / Q000633:toxicity*; D018698:Glutamic Acid; D006400:Hematocrit; D008297:Male; D010069:Oxadiazoles / Q000378:metabolism; D011479:Protamines / Q000494:pharmacology; D011810:Quinoxalines / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D018091:Receptors, AMPA; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors* / Q000502:physiology; D012709:Serum Albumin / Q000134:cerebrospinal fluid
D005971:Glutamates; D010069:Oxadiazoles; D011479:Protamines; D011810:Quinoxalines; D018091:Receptors, AMPA; D017981:Receptors, Neurotransmitter; D012709:Serum Albumin; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D018698:Glutamic Acid